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Background: It remains unclear to what extent asthma in adults is linked to allergic rhinitis (AR), gastroesophageal
reflux disease (GERD), and acetylsalicylic acid exacerbated respiratory disease (AERD), and how these comorbidities may
affect asthma outcomes in the general population. We therefore aimed to assess the prevalence of these major
comorbidities among adults with asthma and examine their impact on asthma exacerbations requiring hospital care.
Methods: A total of 22,050 adults 18 years and older were surveyed in the German National Health Telephone Interview
Survey (GEDA) 2010 using a highly standardized computer-assisted interview technique. The study population comprised
participants with self-reported physician-diagnosed asthma, among which the current (last 12 months) prevalence of AR
and GERD-like symptoms (GERS), and life-time prevalence of AERD was estimated. Weighted bivariate analyses and
logistic regression models were applied to assess the association of each comorbid condition with the asthma outcome
(any self-reported asthma-related hospitalization and/or emergency department (ED) admission in the past year).
Results: Out of 1,136 adults with asthma, 49.6% had GERS and 42.3% had AR within the past 12 months; 14.0% met the
criteria of AERD, and 75.7% had at least one out of the three conditions. Overall, the prevalence of at least one
exacerbation requiring emergency room or hospital admission within the past year was 9.0%. Exacerbation prevalence
was higher among participants with comorbidities than among those without (9.8% vs. 8.2% for GERS; 11.2% vs. 7.6% for
AR, and 22.2% vs. 7.0% for AERD), but only differences in association with AERD were statistically significant. A strong
association between asthma exacerbation and AERD persisted in multivariable logistic regression analyses adjusting for
sex, age group, level of body mass index, smoking status, educational attainment, and duration of asthma: odds ratio
(OR) = 4.5, 95% confidence interval (CI) = 2.5–8.2.
Conclusions: Data from this large nation-wide study provide evidence that GERS, AR and AERD are all common
comorbidities among adults with asthma. Our data underline the public health and clinical impact of asthma with
complicating AERD, contributing considerably to disease-specific hospitalization and/or ED admission in a defined
asthma population, and emphasize the importance of its recognition in asthma care.
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Asthma is a common disease among adults [1,2]. It can
have a substantial impact on the health-related quality
of life and constitutes a high socioeconomic burden on
the health care system [2,3]. Allergic rhinitis (AR), gas-
troesophageal reflux disease (GERD), and acetylsalicylic
acid (ASA) intolerance can be assigned to comorbid
conditions that are commonly related to asthma [4].
These comorbidities are considered highly relevant for
asthma control and exacerbation outcomes [5]. The
consideration and specific management of these co-
morbid conditions is therefore of high importance in
asthma care [6].
Allergic rhinitis and asthma commonly coexist [7,8]. Al-
lergic rhinitis is a risk factor for asthma and may even be
on the same disease continuum as asthma [7,9,10]. The
presence of concomitant AR in adult asthma was associ-
ated with worse asthma outcomes resulting in a higher
risk of asthma-related emergency hospital care in some
studies [7,11,12]. The evaluation and consequent manage-
ment of AR may improve asthma outcomes according to
national and supranational guidelines [6,13,14].
Although an association between gastroesophageal re-
flux disease (GERD) and asthma has also been reported,
the extent and underlying mechanism of this rela-
tionship remain unclear [15-17]. There is controversy
regarding the effect of GERD on asthma outcomes
[5,6,17]. For individuals with asthma and concomitant
GERD-like symptoms prior studies only inconsistently
suggested that treatment of GERD might reduce exacer-
bations [17,18].
Intolerance to ASA or other nonsteroidal anti-
inflammatory drugs (NSAIDs) marks a distinct clinical
entity – ASA exacerbated respiratory disease (AERD), or
ASA-induced asthma (AIA) [19-21]. On the basis of in-
tractable inflammation of the upper and lower airways,
asthma might precede the development of an upper air-
way disease comprised of chronic hypertrophic eosino-
philic sinusitis and nasal polyps or follow it [19,21].
AERD is characterized by a potentially more severe dis-
ease course of asthma [20,22] with a higher likelihood of
an asthma-related emergency department or hospital ad-
mission [22-24]. Its recognition and appropriate man-
agement is crucial to effectively reduce morbidity and
acute severe outcomes [6,21].
AR, GERD and AERD are common conditions among
adults with asthma. To date, however, prevalence esti-
mates of these conditions among adults with asthma
vary widely [16,25,26]. Furthermore, population-based
information on the impact of each condition on asthma
outcome is scarce, especially with regard to exacerba-
tions that considerably increase morbidity and health
care needs [27]. Against this background, we aimed to
assess population-based data on the prevalence of AR,GERS and AERD among adults with asthma and exam-
ine the association of these comorbidities with asthma
exacerbations requiring hospital care in the past
12 months in the framework of a national health inter-
view survey.Methods
Study design and study population
GEDA (“German Health Update”) is a periodically re-
peated national health interview survey of adults (18 years
and older) as part of the continuous health monitoring
system in Germany [28]. The target population for the
2010 GEDA survey comprised all adults residing in private
households with landline telephones who could fluently
speak and understand German language. A two-stage
sampling procedure was applied. A random digit dialing
method was used for sampling at the household level [29].
At the individual level, the ‘last-birthday-method’ was ap-
plied in order to select those adult members of the
contacted households who most recently had their birth-
day prior to the date of the first contact to the respective
household [30].
As the participation in the National Health Telephone
Interview Surveys is voluntary, at no costs to the survey
participants, and because the study has no medical rele-
vance for individual survey participants (no medical re-
search involving human subjects is being conducted) an
ethics approval was not compulsory. In terms of data pro-
tection and informed consent the study was approved by
The Federal Commissioner for Data Protection and Free-
dom of Information. Verbal informed consent was pro-
vided by all participants prior to the interview.
Between September 2009 and July 2010, 22,050 indi-
viduals aged 18 years and older were surveyed at one
particular point in time. The corresponding cooperation
rate at the individual level was 55.8% which represents
the cooperation rate at the respondent level [31]. The
present analysis is restricted to participants with current
physician-diagnosed asthma, defined as an affirmative
response to two consecutive questions about whether
they had ever been told by a physician that they had
asthma and whether it had been present within the past
12 months.Data collection
Information on health status, medical history, health-
related behaviour, socio-demographic and anthropometric
variables was collected based on computer-assisted tele-
phone interviews (CATI). Interviews were performed by
interviewers, who were trained and supervised according
to guidelines of the Behavioral Risk Factor Surveillance
System of the Centers for Disease Control and Prevention,
applying a highly standardized protocol [32].
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on the age of asthma onset, asthma-related health-care
utilization (hospitalizations and emergency department
admissions) and the history of concomitant conditions
(nasal allergy including hay fever, GERD-like symptoms
(heartburn or acid regurgitation), intolerance to analgesics,
and nasal polyps) was assessed and the asthma outcome
was defined as any vs. no exacerbation requiring asthma-
related hospitalizations or emergency department (ED)
admission in the past year. Although it would be ideal to
include information on the application of systemic corti-
costeroids in the definition of an asthma exacerbation
[27], our data permit an approach to define a moderate
asthma exacerbation according to the American Thoracic
Society and European Respiratory Society [27].
Body mass index (BMI) was calculated by dividing self-
reported weight (kg) by height (m) squared. According to
the criteria of the World Health Organization, BMI status
was categorised as obese (BMI ≥30 kg/m2), overweight
(25 kg/m2 ≤ BMI <30 kg/m2) and non-overweight/non-
obese (BMI <25 kg/m2) [33]. Educational attainment was
classified as primary, middle or high according to the 3-
level ISCED (International Standard Classification of Edu-
cation) [34]. Smoking status was classified into three
categories (current, former, and never) [35]. Based on the
respective response to the question ‘Do you smoke – even
occasionally?’ [36], study participants who responded ‘yes,
daily’ or ‘yes, occasionally’ were defined as ‘current’
smokers, those who answered ‘no, I quit smoking’ were
defined as former and those who answered ‘no, I never
smoked’ were defined as ‘never’ smokers.
Statistical analyses
Data analysis was performed using SPSS (Statistical
Package for the Social Sciences) software (version 20,
SPSS Inc. Chicago, IL) with the complex sample module.
A significance level of p < 0.05 was considered statisti-
cally significant based on two-tailed tests. In order to as-
sure representativeness at the population level, all results
were weighted throughout the analyses and reported
along with unweighted numbers of participants. Sample
weights adjust for sampling probabilities and selective
participation (adjusting for deviations between the study
population and German population statistics of Decem-
ber 31, 2008 within strata of age, sex, residential region,
and level of education) [31,37]. For each variable,
weighted proportions are reported along with the un-
weighted n referring to the number of participants who
provided the information. Weighted prevalence of AR,
GERS and AERD as independent study variables and of
the outcome variable (asthma outcome as defined by a
hospitalization and/or ED admission in the past 12 months)
was estimated with a 95% confidence interval (CI).
Weighted bivariate analyses were performed to assess theassociation between asthma comorbidities and covariables
(sex, age groups, BMI status, educational attainment,
smoking status and asthma duration) and the Rao-Scott
chi-square test of independence with second order adjust-
ment was used to test for differences in the distribution of
proportions [38]. Independent associations of asthma
comorbidities with asthma outcome were examined in
multivariable logistic regression models. Sex, chrono-
logical age group (18–29, 30–44, 45–64, ≥65 years), BMI
status (non-overweight/non-obese, overweight, obese),
educational attainment (primary, middle, high), and smok-
ing status (current, former, never) were included as cat-
egorical covariables, and asthma duration in years as a
continuous covariable.Results
Characteristics of the study population
Basic characteristics of the total study population and of
participants with current asthma are summarized in
Table 1. Altogether, 1,136 (5.3%) study participants (737
women, 399 men) of a total sample of 22,050 persons
aged 18 years and older were included in the present
analysis. Their median age at the time of the survey was
52.0 (interquartile range (IQR) 38.0–68.0) years which
was higher than the median age of the total study popu-
lation (48.0; IQR 35.0-64.0). Comparing participants
with current asthma to the total study population, higher
proportions were found among those who were women,
overweight or obese, former smokers and among those
with middle or primary educational attainment. Among
survey participants with current asthma, those who were
women, non-overweight/non-obese, never smokers, or
those with middle educational attainment were the most
numerous. In addition, almost a quarter of individuals
with current asthma were obese. The median asthma
duration at the time of the survey was 15.0 (IQR 6.0–
28.0) years.Prevalence of asthma-related comorbidities and asthma
outcome among adults with current asthma
Altogether, 75.7% of adults with current asthma re-
ported at least one out of three comorbidities: current
allergic rhinitis (AR), current GERD-like symptoms
(GERS) or a history of AERD. Reported by almost half
of the study participants, GERS was more prevalent
than AR among persons with asthma (Table 2). A his-
tory of nasal polyps and AERD were also common con-
ditions. In combination with asthma, these conditions
are known as Samter’s triad [21]. The study outcome
measure – at least one asthma-related hospitalization
and/or emergency department admission in the past
year – was reported by 9.0% of the survey participants
with current asthma.
Table 1 Descriptive characteristics of study participants
of the German National Health Telephone Interview
Survey (GEDA) 2010
Characteristics Current asthma
population
Total
population
(N = 1136) (N = 22050)
Sex, % (n)
Women 61.1 (737) 51.5 (12483)
Age, in years
Mean (±SD) 52.1 (±18.2) 49.0 (±17.9)
Range (18–95) (18–99)
Age groups, % (n)
18–29 years 13.4 (171) 16.9 (3831)
30–44 years 21.5 (276) 25.9 (6096)
45–64 years 35.3 (440) 32.7 (7980)
≥65 years 29.8 (249) 24.4 (4143)
BMI status, % (n)
<25 kg/m2 39.3 (488) 47.8 (11322)
25 – <30 kg/m2 36.7 (387) 36.3 (7338)
≥30 kg/m2 24.0 (237) 15.8 (2931)
Educational attainment,
% (n)
Primary 27.1 (126) 22.1 (2082)
Middle 55.7 (625) 55.5 (11076)
High 17.3 (384) 22.3 (8865)
Smoking status, % (n)
Current 29.7 (322) 30.0 (6291)
Former 31.0 (338) 26.6 (5881)
Never 39.3 (476) 43.4 (9873)
Weighted percentage (%), unweighted n may not add up to total N due to
unknown or missing responses excluded from the analysis.
Table 2 Comorbid conditions and study outcome among stud
Characteristics
Comorbid conditions
History of allergic rhinitis
Current allergic rhinitis (in the past year)
Current GERD-like symptoms (in the past year)
History of AERD
History of nasal polyps
- among AERD cases
- among non-AERD cases
History of AERD and nasal polyps (Samter’s triad)
Study outcome
Any vs. no asthma-related hospitalization/emergency department admission
Weighted prevalence (%) with 95% confidence interval (95%-CI), unweighted count
missing values for outcome study variable are as follows: any asthma-related hospit
missing values. % (n) of missing values for primary independent study variables are
(n = 12). Gastroesophageal reflux disease (GERD); acetylsalicylic acid exacerbated re
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demographic and other correlates among adults with
current asthma
Statistically significant differences in the distribution of
current AR were found according to strata of all covari-
ates but sex (Table 3). Current AR was less prevalent in
relation to increasing age group and BMI level whereas
it was more prevalent in relation to increasing educa-
tional attainment level. The distribution of current AR
differed significantly according to smoking status with
the highest prevalence among never smokers and the
lowest prevalence among former smokers. GERS was
significantly more prevalent in relation to increasing
BMI level. The prevalence of AERD did not show any
significant differences according to covariables.Association between asthma comorbidities and asthma
outcomes
The prevalence of at least one asthma-related
hospitalization and/or emergency department admission
in the past year was higher among asthmatic participants
with comorbidities compared to those without (9.8% vs.
8.2% for GERS; 11.2% vs. 7.6% for AR, and 22.2% vs.
7.0% for AERD), but only differences in association with
AERD were statistically significant (Figure 1). These re-
sults persisted in multivariable models adjusting for
covariables (Table 4). An interaction term for sex with
AERD additionally included in the multivariable model
was non-significant (Additional file 1). There was also
no interaction with age group (<55 years vs. ≥55 years)
(Additional file 2). The above results also persisted when
treating age as a continuous variable in the models (data
not shown).y participants with current asthma (N = 1136)
Unweighted n Weighted % (95%-CI)
678 54.5 (50.6-58.3)
535 42.3 (38.6-46.0)
522 49.6 (45.8-53.4)
138 14.0 (11.3-17.2)
350 29.8 (26.5-33.4)
57 36.9 (26.9-48.2)
287 28.3 (24.8-32.1)
57 5.2 (3.7-7.3)
in the past year 96 9.0 (7.1-11.5)
(n). Unknown or missing responses excluded from the analyses. % (n) of
alization/emergency department admission in the past year 0.1% (n = 2)
as follows: current AR 1.1% (n = 15), current GERS 0.3% (n = 6), and AERD 1.2%
spiratory disease (AERD).
Table 3 Comorbid conditions with respect to covariables among study participants with current asthma (N = 1136)
Characteristics Current allergic rhinitis Current GERS AERD
(yes vs. no) (yes vs. no) (yes vs. no)
Total, % (n) 42.3 (535) 49.6 (522) 14.0 (138)
Age, y
Mean (±SD) 43.8 ±16.4 52.2 ±17.3 53.2 ±16.6
Age, % (n)
18–29 years 68.2 (113)*** 42.1 (72) 6.6 (15)
30–44 years 64.5 (185)*** 52.6 (132) 18.4 (38)
45–64 years 39.7 (188)*** 51.8 (203) 14.4 (51)
≥65 years 17.8 (49)*** 48.3 (115) 13.8 (34)
Sex, % (n)
Men 39.0 (180) 47.2 (181) 13.6 (41)
Women 44.4 (355) 51.2 (341) 14.3 (97)
BMI status, % (n)
<25 kg/m2 51.9 (275)*** 40.0 (184)** 9.9 (48)
25 – <30 kg/m2 40.9 (161)*** 53.6 (195)** 16.1 (54)
≥30 kg/m2 29.2 (86)*** 57.8 (129)** 17.2 (31)
Educational attainment, % (n)
Primary 33.7 (52)** 55.6 (62) 19.6 (20)
Middle 42.4 (282)** 48.2 (296) 12.5 (78)
High 55.8 (201)** 45.3 (164) 10.4 (40)
Smoking status, % (n)
Current 42.3 (140)*** 54.6 (170) 12.4 (37)
Former 30.8 (127)*** 45.9 (145) 13.0 (42)
Never 51.3 (268)*** 48.8 (207) 16.0 (59)
Asthma duration, y
Mean (±SD) 18.4 ±14.1 20.2 ±17.3 18.5 ±16.7
*** p < 0.001, ** p < 0.01, * p < 0.05 obtained from Rao-Scott chi-square test of independence for categorical variables. Unknown or missing responses were
excluded from analysis. Unweighted n may not add up to total N due to unknown or missing responses excluded from the analysis. Gastroesophageal reflux
disease-like symptoms (GERS); acetylsalicylic acid exacerbated respiratory disease (AERD).
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Main findings
We found that more than three quarters of adults with
asthma reported at least one of the assessed comorbid
conditions that are considered highly relevant for
asthma outcomes [5]. In the present analysis, every sev-
enth adult with asthma met the criteria of AERD, a con-
dition that by more than four times increased the
chance of at least one asthma-related hospitalization or
ED admission in the past year. In contrast, we observed
an only weak and non-significant association of GERS
and AR with the study outcome at the population level.
Comparison with other studies
In our study, we estimated a life time prevalence of self-
reported allergic rhinitis of 54.5% among study partici-
pants with asthma. This prevalence estimate is similar to
findings of the German national health interview andexamination survey (GNHIES) 1998 (52% among individ-
uals with asthma) [39]. Our result is also in line with esti-
mates ranging from 28% (1 year prevalence) up to 100%
(life time prevalence) as reviewed for European adults with
asthma [26]. Cardinal symptoms of GERD (heartburn or
acid regurgitation) were currently present among 49.6% of
all study participants with asthma. A systematic review
showed similar prevalence estimates of GERD symptoms
ranging between 45.0% and 71.0% [16]. Finally, we esti-
mated an AERD prevalence of 14.0% among individuals
with asthma which is in the range of reported AIA preva-
lence varying from 1.9% to 44% among individuals with
asthma [24,25,40,41]. In line with our results, AIA preva-
lence estimates of up to 13.6% were obtained from other
population-based surveys among unselected adult asthma
populations in Europe and Australia [24,40-42].
Our results regarding the impact of AERD on asthma-
specific hospitalizations and/or ED admission are in line
Figure 1 Asthma-related hospitalizations/emergency department admissions in the past year with regard to comorbidities. Weighted
prevalence (%) of any vs. no asthma-related hospitalization and/or emergency department admissions in the past year among study participants
with asthma with regard to concomitant comorbid conditions. *** p < 0.001 obtained from Rao-Scott chi-square test of independence with
second order adjustment. Gastroesophageal reflux disease-like symptoms (GERS); acetylsalicylic acid exacerbated respiratory disease (AERD).
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phenotype has been characterized by frequent exacerba-
tion of symptoms and an increased risk of progressive
airflow obstruction compared to ASA-tolerant persons
with asthma in a selected patient study [20,22]. In this
study, significant differences between the two cohorts
were also found with respect to emergency department
admissions among individuals with AERD (18%; n = 81)
compared to those without (13%; n = 372, p = 0.017)
[22]. Individuals with AERD also showed a higher pro-
portion of hospitalizations: 6% (n = 29) vs. 5% (n = 131),
p = 0.068 [22]. Likewise in a case comparison with com-
munity control, the odds ratio of an hospitalization for
acute asthma was more than three times increased for
ASA/NSAID-intolerant asthma patients compared toTable 4 Association of each comorbidity with any vs. no asth
Any vs. no asthma-
related hospitalization/
ED admission in the
past year
Current allergic rhinitis
(yes vs. no)
OR (95%-CI)
Model 1 n = 1120
no 1.00
yes 1.53 (0.90–2.62)
Model 2 n = 1120
no 1.00
yes 1.41 (0.83–2.40)
Model 3 n = 1044
no 1.00
yes 1.30 (0.75–2.26)
Odds ratio (OR) with 95% confidence interval (95%-CI) obtained from logistic regres
*Model 1, unadjusted; model 2, adjusted for age group (18–29, 30–44, 45–64, ≥65)
educational attainment, smoking status, BMI status, and asthma duration. Gastroeso
respiratory disease (AERD).ASA/NSAID-tolerant asthma patients (OR = 3.63; 95%-
CI = 1.70-7.74) [23]. Additionally in a population-based
study, significant differences were found with respect to
the prevalence of an asthma-specific emergency depart-
ment admission: 28.8% (n = 52) among individuals with
AIA vs. 12.2% (n = 135) among subjects with ASA-
tolerant asthma and with respect to an asthma-specific
hospitalization: 15.0% (n = 27) vs. 6.2% (n = 69) [24].
We cannot exclude the possibility that aspects of self-
management such as good medication adherence or
proper inhalation technique [43] influenced the asthma
outcome. Moreover, discordant comorbidity such as men-
tal disorders [44] may have contributed but this was be-
yond the scope of the present analysis. However, worse
outcomes among persons with AERD may, in part, alsoma-related hospitalization/ED admission in the past year
Current GERS AERD
(yes vs. no) (yes vs. no)
OR (95%-CI) OR (95%-CI)
n = 1128 n = 1122
1.00 1.00
1.23 (0.72–2.10) 3.78 (2.03–7.04)
n = 1128 n = 1122
1.00 1.00
1.26 (0.73–2.17) 4.06 (2.20–7.47)
n = 1051 n = 1045
1.00 1.00
1.12 (0.64–1.98) 4.49 (2.47–8.16)
sion models.
and sex; model 3, adjusted for age group (18–29, 30–44, 45–64, ≥65), sex,
phageal reflux disease-like symptoms (GERS); acetylsalicylic acid exacerbated
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such as ASA desensitization followed by daily ASA inges-
tion [19] or treatment with leukotriene modifiers [6,20],
contributing to the integral management of this complex
disease. Given that AERD constitutes a considerable part
of the general adult asthma population, future clinical and
epidemiological research is thus needed to understand
whether AERD populations are adequately managed and
to what extent disease outcomes might be modifiable by
optimal care.
We found that at the population-based level the pres-
ence of cardinal symptoms of GERD did not result in a
significantly higher chance of at least one asthma-related
hospitalization or ED admission in the past year. It has
previously been hypothesized that GERD may act as a po-
tential asthma trigger through various mechanisms by in-
creasing airway inflammation and airway responsiveness
[17]. Treatment studies, however, only inconsistently sug-
gested an association between GERD and asthma out-
comes [17]. Moreover, asthma exacerbation outcome was
not significantly affected by long-term proton-pump in-
hibitor (PPI) treatment among asthmatics with symptoms
suggestive of GERD in a large recent randomized con-
trolled trial (RCT) [18]. In contrast, other authors of a
large RCT observed a significant reduction in moderate-to-
severe asthma exacerbations due to PPI treatment (4% vs.
13.9%, respectively; p = 0.016) [45].
Moreover, we found that the size of the independent
effect of current AR on the study outcome measure was
low and non-significant. Both conditions are considered
to be linked and to interact on the basis of a common
inflammatory process. AR might also affect asthma by
other means such as an impairment of the air-
conditioning and filtering function of the nose or an in-
crease in mouth breathing due to nasal obstruction,
resulting in a higher exposure of the lower airways to
airborne asthma triggers [7,46]. In the published litera-
ture, concomitant AR appears to have an impact on
asthma outcomes; to what extent, however, is still under
debate [5,7,8,10,46]. A retrospective observational study
based on a general practice database and a post hoc ana-
lysis of a clinical trial assessed the association of concur-
rent AR with asthma outcomes in adults. In both studies
moderate ORs for an asthma-related hospitalization
(pooled with asthma-related emergency department ad-
missions) (adjusted OR = 1.52; 95%-CI = 1.03–2.24) [12]
and on asthma-related emergency department admis-
sions (adjusted OR = 2.32; 95%-CI = 1.12-4.80) [7,11]
were reported. In contrast, fewer asthma-related hospi-
talizations (adjusted p = 0.01) were observed among
atopic asthma patients with nasal symptoms (mean
number = 0.2) compared to those without (mean num-
ber = 0.6) in a retrospective observational study based on
medical records of a university-based asthma clinic[7,47]. Moreover, prior literature suggests that treatment
of concomitant AR in persons with asthma can influence
asthma outcomes and reduce asthma exacerbations
[7,8,10]. The recognition and consequent management
of AR in asthma has thus been promoted by national and
supranational guidelines during recent years [6,14,48,49].
Therefore, the insignificant effect of AR on the study out-
come might reflect improved clinical management of AR
within the general asthma population.
Limitations and strengths
The present study was of cross-sectional design and infor-
mation on the presence of current asthma and related
comorbidities was based on telephone interviews. Hence,
some limitations need to be discussed. First, our case def-
inition of current asthma was based on an interview ques-
tionnaire and did not include objective measurements.
However, Kilpeläinen et al. showed that a questionnaire-
based definition of physician-diagnosed asthma had ac-
ceptable levels of positive predictive value and speci-
ficity and can be considered a suitable method of
assessment in epidemiological studies [50]. Second, we
cannot rule out misclassification with respect to AR and
AERD. Regarding the history of AERD, we must con-
sider that the gold standard for the diagnosis of AERD
in clinical studies is a graded ASA provocation test [20]
whereas a questionnaire-based assessment of the pa-
tient’s history would reveal lower prevalence estimates
than the objective assessment based on oral provocation
testing [25]. In large population-based studies, self-
reported information is often the only feasible option.
Notwithstanding these limitations, our prevalence esti-
mates of concomitant current AR and of AERD as well
as of cardinal symptoms of GERD lie in the range of re-
sults obtained on the basis of questionnaires discussed
in recent reviews [16,25,26].
Third, we could not perform non-response analyses
based on information collected for non-responders and
responders. However, all data were carefully weighted to
adjust for sampling design and non-response in order to
represent the adult residential population of Germany
and to extend the generalizability of our results to the
general population. Finally, the cross-sectional study de-
sign does not allow conclusions to be reached regarding
the cause-effect relationship(s) of comorbidity in asthma
patients; therefore, our results need to be interpreted
with caution.
The major strength of the study is that our analyses
were based on a large population-based sample of the
German adult population, allowing us to quantify the
impact of major comorbid conditions in a general
asthma population. Our study adds to the limited know-
ledge on specific comorbidity asthma outcome relations
throughout adult life. We have been able to show that
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ably to increased disease-specific hospital contacts in the
general asthma population. Our findings are thus of
interest for both clinicians in primary and specialist care.
In addition, our data underline the socio-economic im-
pact of asthma with complicating AERD and are relevant
for the organization of health care.
Conclusions
Three quarters of German adults with asthma had at least
one of the 3 following comorbidities GERS, AR, AERD.
Our results underline the public health relevance and im-
portance of recognizing major comorbidities in asthma
care. Particularly AERD contributes considerably to hos-
pital contacts in the asthma population. Further clinical
and epidemiological research is needed to determine
whether the clinical management of specific asthma popu-
lations is consistent with current recommendations and to
what extent disease outcomes might be improved by opti-
mal care.
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